Physician profile
Nader Aziz
NPI 1396829727
$24,113.11
in general payments reported to CMS, 2019-2025
61 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,133 · 2020: $3,458 · 2021: $5,017 · 2022: $6,626 · 2023: $3,878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,798 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,798.23 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,145.31 | 2019-2023 | Farxiga, Breztri, Fasenra |
| Merz North America, INC. | $2,618.16 | 2019-2023 | Xeomin |
| Amgen INC. | $1,798.85 | 2019-2023 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $1,560.20 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $1,452.54 | 2019-2023 | Ubrelvy, Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,143.64 | 2019-2023 | Jardiance, Synjardy, Spiriva Respimat |
| Glaxosmithkline, LLC. | $1,033.37 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $880.54 | 2019-2023 | |
| Novo Nordisk INC | $840.45 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $563.51 | 2019-2023 | |
| Allergan, INC. | $562.73 | 2019-2022 | |
| Bausch Health US, LLC | $499.08 | 2019-2023 | Aplenzin, Wellbutrin |
| Sanofi-Aventis U.S. LLC | $492.64 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $470.97 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $454.08 | 2019-2023 | Rexulti |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nader Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.